ADAMTS13 activity should be closely monitored in patients with a history of acute TTP, and plasma infusion should be given if ADAMTS13 activity is <10% and antibody (inhibitor) is negative. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.